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Communicated by Riccardo Fodde 
Hereditary Non-Polyposis Colorectal Cancer (HNPCC) is associated with germline 
mutations in one of several MisMatch Repair (MMR) genes. An increasing proportion (20-
25%) of the reported MSH2 variants consists of single amino-acid substitution with 
uncertain disease-causing significance. The present study was undertaken to functionally 
characterize 3 MSH2 nontruncating variants: p.Gly162Arg (c.484G>C), p.Asp167His 
(c.499G>C) and p.Arg359Ser (c.1077A>T). Missense alterations, were assessed in a human 
system for expression/stability and for the ability to heterodimerize with MSH6 and 
correctly localize into the nucleus. Functional assays results were correlated with clinical 
and genetic features indicative of HNPCC as MicroSatellite-Instability (MSI), abnormalities 
of MMR gene expression in tumour tissue (IHC) and familial history. p.Gly162Arg and 
p.Arg359Ser variants showed a clearly decreased expression level of the MutSα complex and 
were associated with an abnormal subcellular localization pattern, which can be suggestive 
of an incorrect MSH2/MSH6 heterodimerization. Functional analysis results were supported 
by MSI and IHC data and by familial cancer history. The subcellular localization assay, 
performed in a human expression system, classifies as pathogenetic two MSH2 
nontruncating alterations providing a useful tool in genetic testing programs. © 2008 Wiley-
Liss, Inc. 
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INTRODUCTION 
Hereditary Non-Polyposis Colorectal Cancer (HNPCC; MIM# 120435) is a dominantly inherited cancer 
susceptibility syndrome which accounts for 3-5% of all colorectal tumours (de la Chapelle 2005). HNPCC 
syndrome is characterized by an increasing lifetime risk of colorectal as well as of other cancers such as 
endometrium, stomach or small bowel and is genetically associated with germline mutations in one of several 
postreplicative DNA MisMatch Repair (MMR) genes, mostly MLH1 (MIM# 120436), MSH2 (MIM# 609309), 
and, in fewer cases, MSH6 (MIM# 600678) or PMS2 (MIM# 600259) (Lynch and de la Chapelle 2003). MMR 
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reverses base to base mismatches and slippages in simple repeat sequences that escape the DNA polymerase 
proofreading activity (Kunkel and Erie 2005). 
For successful accomplishment of the MMR activity, the MSH2 and MSH6 repair proteins have to 
heterodimerize to constitute the MutSα complex and correctly translocate from the cytoplasm into the nucleus 
through NLS-importin α/β shuttling mechanism (Iyer et al. 2006, Knudsen et al. 2007, Stewart 2007). Defects in 
MMR activity result in a mutator phenotype that leads to increase spontaneous somatic mutation rate, particularly 
in multi simple repeats non-expressed sequences (microsatellite) (Peltomaki 2003, Kunkel and Erie 2005). Nearly 
500 different and likely pathogenetic germline alterations affecting mostly the MLH1 (50%), MSH2 (39%) and 
MSH6 (7%) MMR genes are listed in the international HNPCC mutations database (Peltomaki and Vasen 2004). 
Although the majority of MSH2 associated mutations result in premature termination of translation, a significant 
and increasing proportion (20-25%) of the reported MSH2 variants give rise to single amino acid substitution 
(Peltomaki and Vasen 2004, Ollila et al. 2006, Woods et al. 2007). 
Disease-causing nontruncating mutations can be distinguished from non-pathogenic variants by evaluating 
some well defined criteria: co-segregation with the disease, low incidence of the alteration in the general healthy 
population, non conservative status of the amino acidic change, evolutionary conservation of the involved codon, 
and, in cases of suspected HNPCC, correlation with MicroSatellite Instability (MSI) and loss of MMR proteins in 
tumour tissue (Genuardi et al. 1999, Cravo et al. 2002). However, rare polymorphisms can result in a non-
conservative amino-acid change and segregation studies are rarely feasible because of ethical issues, limitations of 
family size and/or unavailability of biological specimens (Trojan et al. 2002, Kondo et al. 2003). In addition, the 
biochemical significance of these alterations is often uncertain and loss of MMR gene expression and MSI could 
represent the result of somatic mutations or epigenetic silencing (Cravo et al. 2002, Nystrom-Lahti et al. 2002, 
Yuen et al. 2002). In such cases, the nature of the inherited MMR mutation and its role in colorectal cancer 
susceptibility should be further analysed by other means. 
In order to provide informations about the effect of the HNPCC-related gene variants on the function of the 
corresponding MMR polypeptide, several functional assays have been developed (Shimodaira et al. 1999, 
Guerrette et al. 1999, Shcherbakova and Kunkel 1999 Ellison et al. 2001, Brieger et al. 2002, Nyström-Lahti et al. 
2002, Trojan et al. 2002, Kondo et al. 2003, Ellison et al. 2004, Raevaara et al. 2005, Belvederesi et al. 2006, Blasi 
et al. 2006, Takahashi et al 2007). 
Contrary to MLH1 missense mutations, which have already been deeply assessed, there is a poor knowledge 
about the pathogenicity of MSH2 non truncating variants. Nearly all the already known MSH2 related assays are 
based on a biochemical approach (Kijas et al. 2003, Heinen et al. 2002) or conducted in a heterologous system 
(Ellison et al. 2001, Gammie et al. 2007). To our knowledge, only one recent study (Ollila et al. 2006) aimed to 
functionally characterise MSH2 missense variants in a human expression system and to date no pathogenic 
assessment dealing with MSH2 protein localization defects have been established. 
The present study was undertaken to investigate, in a human expression system, the effects of 3 MSH2 
nontruncating variants, found in suspected HNPCC families, on subcellular localization of the corresponding 
protein and successively to validate such assay as a tool for MSH2 pathogenic assessment. To this aim, we both 
compared localization assay results to those obtained by less innovative approaches (expression/interaction assays) 
and correlated such results with in silico predictive alignment sequence analysis and with clinical data, such as 
familial cancer history, occurrence of MSI and abnormalities of MMR gene expression in the tumour tissue. 
 
PATIENTS AND METHODS 
HNPCC families and MSH2 mutations 
Among the clinically characterised missense mutations identified in patients referred to our Centre for genetic 
counselling, only the ones for which functional data were available in the literature were included in the present 
study. The 3 MSH2 mutations were identified in 5 patients belonging to 3 unrelated HNPCC families. All the index 
patients had a family history fulfilling at least one of the Bethesda guidelines (Rodriguez-Bigas et al. 1997, Umar 
et al. 2004) and subscribed written informed consent to genetic testing and to the additional studies required for 
this work. 
Mutational analysis was performed on genomic DNA purified from peripheral mononuclear blood cells, 
according to standard procedures. All the MLH1 and MSH2 exons, including flanking intronic regions, were 
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individually amplified and directly sequenced using Applied Biosystems ABI PRISM 310 automated sequencer 
and the Big Dye terminator Cycle Sequencing Ready Reaction-Kit (Applied Biosystems, Foster City, CA) as 
previously described (Scartozzi et al. 2002). Identified mutations were confirmed on a second sample PCR 
product. Primer sequences are available from the corresponding Author upon request. 
The prevalence of each variant was evaluated in the germline of a reference population panel of 100 healthy 
blood donors and compared with the international HNPCC database (http://www.insight-group.org). Multiplex 
Ligation-dependent Probe Amplification (MLPA) was applied to exclude large genomic rearrangements and 
performed as previously described (Bianchi et al. 2007). A 40–55% decrease of the area of an MSH2 or MLH1 
exon peak compared to the wild-type control samples was considered as indicative of a heterozygous deletion of 
that exon. 
 
MSI and Immunohistochemical Analyses 
Colorectal cancer DNA was investigated for MSI using the 5-markers panel (two mononucleotide repeats – 
BAT25 and BAT26- and three dinucleotide repeats –D2S123, D5S346, D17S250) recommended by international 
guidelines (Boland et al. 1998). 
Microsatellite sequences were PCR amplified from tumour and matched normal DNA using 5’- fluorochrome 
labelled oligonucleotide primer pairs (Belvederesi et al. 2006). PCR products were analysed by capillary gel 
electrophoresis (ABI 310 Genetic Analyzer -Applied Biosystems) followed by automated allele sizing using the 
GeneScan 3.7 software (Applied Biosystems, Foster City, CA). PCR primers and conditions are available from the 
corresponding Author. Tumours were classified as highly unstable (MSI-H) when instability was found in at least 
40% of the analysed microsatellite markers. ImmunoHistoChemical (IHC) analysis of MLH1, MSH2 and MSH6 
protein expression was performed on 2 μm sections of paraffin-embedded tumour tissue samples, following 
antigen retrieval (Marcus et al. 1999). The following primary antibodies and dilutions were used: anti-MLH1 
protein (clone G168-728, PharMingen, San Diego, CA), 1:50 dilution; anti-MSH2 protein (clone FE11, 
Calbiochem/Oncogene Research Products, Cambridge, MA), 1:100 dilution; anti-MSH6 protein (clone H-141, 
Santa Cruz Biotechnology, Santa Cruz, CA) 1:250 dilution. 
 
Comparative sequence analysis 
The Sorting Intolerant From Tolerant (SIFT) software (http://blocks.fhcrc.org/sift/SIFT html) was adopted to 
predict the effects of MSH2 amino-acid substitutions on protein functions (Ng and Henikoff 2003). SIFT 
algorithm, through alignments of homologue and evolutionary conserved sequences, calculates normalized 
probabilities for all possible substitutions from the alignments and classifies all potential amino-acid variants as 
tolerated or deleterious. Positions with normalized probabilities less than .05 are predicted to be deleterious, those 
greater than or equal to .05 are predicted to be tolerated (Ng and Henikoff 2003). Program default settings were 
used. 
 
Cloning of MSH2 and MSH6 genes 
The entire MSH2 (GenBank NM_000251.1) and MSH6 (GenBank NM_000179.2) encoding regions were RT-
PCR amplified from the MMR-competent 293 human cell line, using engineered primers bearing the BamHI - 
XhoI restriction sites. (Primer sequences and PCR conditions are available from the corresponding Author). The 
resulting PCR products were directionally cloned into the pCAN-TAGs eucariotic expression vector, a 
modification of pcDNA3 (Invitrogen, Carlsbad, CA) containing an oligoaminoacidic myc-Tag upstream the 
Multiple Cloning Site (MCS). The in frame expression of the myc-Tag and the amino terminus of MSH2 or MSH6 
generates the myc-MSH2 and myc-MSH6 tagged fusion protein (recombinant constructs were referred as pCAN-
myc-MSH2 and pCAN-myc-MSH6). MSH2 cDNA was also subcloned between the same restriction sites of 
pGEX4T-1 (Amersham Bioscience, Piscataway, NJ) bacterial expression vector to generate the Glutathione-S-
Transferase-MSH2 fusion protein GST-MSH2 (pGEX-MSH2). The whole Open Reading Frame (ORF) of MSH2 
and of MSH6, including the insertion sites in the expression vectors, were verified by direct DNA sequencing. 
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Site direct mutagenesis and vectors production 
A PCR based site-directed mutagenesis method (Nystrom-Lahti et al. 2002) was used to reproduce the three 
MSH2 missense mutations found in our HNPCC patients: MSH2(p.G162R), MSH2(p.D167H) and 
MSH2(p.R359S). Two further variants, MSH2(p.P622L) and MSH2(c.2633_2634delAG, p.Glu878fsX3), thought 
to compromise the correct subcellular localization and to impair the MSH2/MSH6 heterodimerization respectively 
(Knudsen et al. 2007, Heinen et al. 2002), were generated. All variants numbering is based on MSH2 cDNA 
sequence (GenBank NM_000251.1) and uses the major translation initiation site as codon 1. 
PCR products containing the mutation were directionally ligated between the BamHI and HindIII cloning sites 
into the template construct pGEX-MSH2 replacing the corresponding wild-type (WT) region. The following 
constructs were obtained: pGEX-GST-MSH2(p.G162R), pGEX-GST-MSH2(p.D167H) and pGEX-GST-
MSH2(p.R359S). 
For protein expression in human LoVo cells, the resulting MSH2 mutant derivatives were subcloned into the 
pCAN-TAGs expression vector between BamHI and XhoI restriction sites to obtain pCAN-myc-MSH2(p.G162R), 
pCAN-myc-MSH2(p.D167H) and pCAN-myc-MSH2(p.R359S). The introduction of the specific mutation and the 
absence of undesired second site sequence alterations were confirmed by sequence analysis. PCR primers and 
conditions are available from the corresponding Author. 
For fluorescent protein production, the WT MSH2 cDNA was cloned into the pEGFP-N1 vector (BD 
Biosciences, Palo Alto,CA) between the XhoI and BamHI restriction sites and in frame with the amino terminus of 
the Enhanced Green Fluorescent Protein (EGFP) encoding gene. The resulting construct expressing MSH2-EGFP 
fluorescent fusion protein is reported here as pEGFP-MSH2. The mutant MSH2 derivatives pEGFP-
MSH2(p.G162R), pEGFP-MSH2(p.D167H) and pEGFP-MSH2(p.R359S) were generated to the pEGFP-MSH2 
plasmid between the XhoI and HindIII sites by site-directed mutagenesis as described above. 
 
Expression of MSH2 and MSH6 in LoVo and 293 cells 
In order to assess the MutSα proteins expression levels in a suitable homologue system, a total of 2 X 106 
MMR-deficient LoVo adenocarcinoma cells were transiently co-transfected with 1 μg of pCAN-myc-MSH2 (WT 
or mutant) and pCAN-myc-MSH6 recombinant expression vectors using LipofectAMINTM 2000 transfection 
reagent (Invitrogen) as specified by the manufacturer. pCAN-TAGs vector without insert was transfected as mock 
control. 
For total protein extraction, cells were harvested 48h after transfection and lysed into cold extraction buffer 
(Belvederesi et al. 2006). Equal amounts (60 μg) of the whole cell lysate were resolved by 6% SDS-PAGE and 
electroblotted to a PVDF membrane (Millipore, Bedford, MA). The expression levels and correct sizes of MutSα 
recombinant proteins, myc-MSH2 and myc-MSH6, were assessed by Western immunoblotting using a mouse 
monoclonal primary antibody (Clone 9E10, 1:600 dilution, Santa Cruz Biotechnology) specific for the myc-Tag of 
the fusion proteins. 
Amounts of 6 X 106 MMR proficient 293 human cells were transiently transfected with 6 μg of purified pCAN-
myc-MSH6 vector mixed with 40 μl of LipofectAMINTM 2000 (Invitrogen). Cells were lysed 48h after transfection 
and the effective ectopic over-expression of the myc-Tag fused MSH6 protein was verified by SDS-PAGE and 
Western immunoblot analysis using the anti-myc-Tag primary antibody as described above. As endogenous MSH6 
was weakly expressed in 293 cells (data not shown), pooled 293 transfected cells lysates were used as a source of 
WT MSH6 protein for the MSH2/MSH6 interaction assay as described in the following paragraph. 
 
GST fusion protein interaction assay 
Wild-type and site-directly mutated MSH2 cDNAs were cloned into pGEX4T-1 vector and expressed into 
competent Escherichia coli BL21 cells as GST-fused MSH2 proteins. Recombinant MSH2 proteins were purified 
using a GST pull-down method as previously described (Guerrette et al. 1998). Wild type MSH6 was cloned into 
pCAN-TAGs vector and retrieved as ectopic over-expressed form from 293 (MMR+) lysates. 
Amounts of BL21 total extracts evaluated to contain equal quantities of recombinant MSH2 (about 800 ng) 
were pre-bound to glutathione-agarose beads and incubated for 2h with 293 cell lysate expressing wild type myc-
MSH6, in 500 μl of binding buffer (Belvederesi et al. 2006). Agarose beads-bound proteins were successively 
resolved by 6% SDS-PAGE. The interaction of MSH2 variants with their biochemical partner MSH6 to constitute 
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the MutSα heterodimer was detected by Western immunoblotting analysis with a mouse monoclonal antibody 
(dilution 1:600) against the MSH6 myc-tag (Clone 9E10, Santa Cruz Biotechnology). In order to confirm that 
equal amounts of WT or mutant GST-MSH2 proteins were used in the assay, the same PVDF membrane was 
subsequently probed with a monoclonal antibody to the MSH2 protein (clone FE11, 1:100 dilution, 
Calbiochem/Oncogene Research Products). 
 
Subcellular localization analysis 
For the expression of WT or mutant EGFP-MSH2 fluorescent fusion proteins in 293 cells, the transfection 
procedure was similar to as previously described except that 0.5 X 106 293 cells were seeded onto polylysine 
treated (0.1 mg/ml) glass coverslips and culture medium was replaced 6 hours after transfection. 
For fluorescent EGFP-MSH2 fusion proteins detection, the 293 cells were fixed 24 hours after transfection with 
a paraformaldehyde solution (4% in PBS, pH 7.4) for 20 minutes at room temperature and stained with a 1μg/ml 
solution of the DNA intercalating specific dye 4’,6-DiAmidino-2-PhenylIndole (DAPI) (Sigma Aldrich, St Louis, 
MO). Subcellular localization of EGFP-MSH2 recombinant proteins was analysed by direct fluorescence using an 
Imager A1 microscope with a 63X objective (Zeiss, Thornwood, NY). Representative images were captured with 
Axio Cam MRC5 and processed with Axio Vision software (Zeiss). Images were representative for at least 80% of 
the transfected cells analyzed. At least 100 cells, from each of the three individual transfection we performed, were 
analyzed from randomly sampled microscope fields of view. 
 
RESULTS 
Patients, genetic studies and tumour phenotypes 
Three germline MSH2 missense mutations were identified in 5 patients belonging to 3 unrelated families who 
underwent genetic testing for suspected HNPCC (Table 1). The mutations were c.484G>C (p.Gly162Arg), 
c.499G>C (p.Asp167His) and c.1077A>T (p.Arg359Ser). All variants numbering is based on MSH2 cDNA 
sequence (GenBank NM_000251.1) and uses the A of the ATG translation initiation start site as nucleotide +1. 
These genetic variants affected conserved amino-acid residues causing non conservative amino-acid changes 
(Ng and Henikoff 2003), were not listed among the known MSH2 polymorphisms reported in inSiGHT database 
and were not found in a control group of 100 healthy volunteers. Furthermore MLPA analysis did not show any 
evidence of large genomic rearrangements in MLH1 and MSH2 genes. 
The p.G162R mutation was found in a 55 years old patient who developed two synchronous colorectal cancers 
and whose family history complied with the Bethesda criteria (2 guidelines). The assessment of the MSI showed 
instability of 3 out of the 5 microsatellite markers. IHC showed normal MLH1 expression and loss of MSH2 and 
MSH6 protein expression. The p.D167H mutation was found in a patient who was diagnosed with an 
adenocarcinoma of the right colon at 42 years of age, without any significant family history of HNPCC-related 
tumours (Scartozzi et al 2002). IHC showed loss of MLH1 protein expression whereas the immuno-expression of 
MSH2 and MSH6 was normal. MSI and MLPA analysis were inconclusive because of the low quantity of 
germline DNA and tumour tissue specimens. The p.R359S mutation was found in 3 related patients whose family 
history fulfilled the Amsterdam II criteria showing a typical HNPCC pedigree (Bianchi et al. 2007). Index patient 
MSI analysis resulted in a high degree of instability (80%). Normal staining for MLH1 and the lack of MSH2 and 
MSH6 expression were observed in the tumour tissue. MLPA analysis did not show other germline abnormalities 
of MLH1 and MSH2 which could be responsible of the strong HNPCC phenotype of this patient. Phenotypic 
characteristics of the variants included in the present investigation are listed in Table 1. 
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Table 1. Clinical, genetic and functional features associated with the three MSH2 missense variants. 
 
 
Age Family history 
 
AA 
change 
 
Type        
AA change SIFT MSI 
IHC 
MSH2
IHC 
MSH6
IHC 
MLH1 Expression
Interaction 
MSH2/MSH6 Localization 
Relationship 
with HNPCC 
55 Beth. p.G162R Nonpolar→ Basic D 60% - - + Reduced + 
Altered 
(nucleus+cytoplasm) Likely 
42 Beth. p.D167H Acidic→ Basic D ND + + - Normal + 
Normal 
(nucleus) Unlikely 
59 Amst. II p.R359S 
Basic→ 
Uncharged 
polar 
D 80% - - + Reduced + Altered (cytoplasm) Likely 
 
Sequence variants numbering is based on MSH2 cDNA sequence (GenBank NM_000251.1) and uses the ATG translation 
initiation site as codon 1. NOTE: Amst., patients fulfilling the Amsterdam Criteria; Beth., patients fulfilling at least one of the 
Bethesda Guidelines; D, amino-acidic substitution predicted deleterious (score ≤.05) by SIFT software; ND, not diagnostic; 
WT, wild type; MSI, percentage of the microsatellite markers showing instability. 
 
Function – structure relationship 
Comparative sequence analysis system (SIFT software) was used to predict the outcome of the three MSH2 
missense variants under study, utilizing the standard alignment and a cut-off score of .05. Each of the three 
assessed variants was reliably (median conservation value less than 3.25) classified as deleterious by SIFT with a 
score next to o.oo. Two out of the three variant sorted as intolerant showed functional defects suggesting a good 
accuracy for pathogenicity prediction. 
 
Expression of MSH2 and MSH6 in LoVo human cells 
An accurately regulated steady state expression level of the MSH2/MSH6 repair proteins is required for 
successful MutSα heterodimerization and accomplishment of the MMR activity. As in absence of its biochemical 
partner MSH2, endogenous MSH6 results unstable and undergoes to a post-translational downregulation of the cell 
level (Chang et al. 2000, Brieger et al. 2002), the effects of the MSH2 missense variant on protein stability were 
studied in LoVo human expression system following transient co-transfection with wild type MSH6. 
Anti-myc Western blotting analysis (Figure 1) compares the MSH2-mutated protein expression levels with the 
MSH2-WT ones in co-transfected LoVo cells. Co-transfection with pCAN-myc-MSH2(p.D167H) resulted in a 
myc-MSH2 protein expression level similar to that referred to MSH2-WT, whereas a clearly decreased expression 
level of myc-MSH2 and myc-MSH6 proteins was detected co-transfecting pCAN-myc-MSH6 with pCAN-myc-
MSH2(p.G162R) or pCAN-myc-MSH2(p.R359S), suggesting that these MSH2 variants were rather unstable 
and/or unable to completely bind and stabilize MSH6 in vivo. Expression level reflecting amounts of MSH2 
similar or lower than the WT were respectively classified as normal or reduced (Table 1). 
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Figure 1. Analysis of expression levels of recombinant MSH2 variants co-
expressed with MSH6 in human LoVo cells. Extracts were prepared 48h 
after co-transfection of LoVo cells with pCAN-myc-MSH2, wild-type or 
mutant, and pCAN-myc-MSH6 vectors. Equal amounts of total cell extract 
were resolved on 6% SDS-PAGE and analysed by western 
immunoblotting using a monoclonal anti-myc antibody to detect the 
expression of myc-MSH2 and myc-MSH6 fusion protein. Mock control: 
cell lysate transfected with empty pCAN-TAGs expression vector. 
MSH2-MSH6 in vitro interaction assay 
The MSH2 protein exists mainly as a complex with MSH6, known as MutSα, which is essential for MMR 
activity. The inability of HNPCC-linked MSH2 variants to interact with MSH6 could result in loss of MMR 
functionality and led to cancer susceptibility. 
Although the 3 missense mutations we found did not occur within the two MSH2/MSH6 interaction domain 
(Guerrette et al. 1998), an alteration of the tridimensional protein conformation is not excluded. In order to 
investigate the effect of the three HNPCC related MSH2 missense mutations on MSH2/MSH6 binding 
impairment, we performed a combined GST-pull-down assay and anti-myc Western immunoblotting analysis. 
These experiments showed that none of the three MSH2 missense mutations MSH2(p.G162R), MSH2(p.D167H) 
and MSH2(p.R359S) yielded polypeptides that were unable to interact with their cognate partner MSH6. The c-
term truncating MSH2 mutation (p.Glu878fsX3), thought to be able to impair such MSH2/MSH6 interaction, 
reduced but did not completely abolish MutSα assembly (Figure 2a). 
In order to ascertain that an equivalent amount of each GST-MSH2 mutant was used in the interaction assay, 
the immunoblotted membranes were re-analysed with an anti-MSH2 antibody. As shown in Figure 2b, both 
MSH2-WT and each of the four MSH2 variants, including the truncating one, expressed comparable amounts of 
recombinant GST-tagged MSH2 polypeptides. No expression is detectable in the lane referred to the mock control 
(pGEX4T-1 vector without MSH2 cDNA). 
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Figure 2. MSH2 germ-line mutations effect on MSH2-MSH6 
heterodimerization. (a) In vitro interaction between WT or recombinant 
MSH2 variants and WT MSH6. Purified GST-MSH2 proteins, expressed 
in E. coli bacterial system, were incubated with a 293 total cell lysate 
expressing myc-MSH6. Assembly of the GST-MSH2/myc-MSH6 
complex was detected by western immunoblotting with a monoclonal 
antibody to the myc-tag (b) Amounts of wild-type or mutant GST-MSH2 
protein used in the MSH2/MSH6 interaction test. The PVDF membrane 
used to study the assembly of the MSH2/MSH6 complex (a) was probed 
with a monoclonal antibody to the MSH2 protein. Mock control: bacterial 
lysate transformed with empty pGEX4T-1 vector. 
 
Subcellular localization assay 
Defects in subcellular localization of the repair proteins result in a MMR-deficient phenotype, making nuclear 
import of MMR components a limiting step for the MMR repairing functions (Wu et al. 2003, Brieger et al. 2005, 
Knudsen et al. 2007). 
As endogenous 293 MSH6 expression level was sufficient to drive the correct nuclear import of the 
MSH2/MSH6 preformed cytoplasmic MutSα complex (data not shown), location of WT and mutated EGFP-
MSH2 fluorescent fusion proteins was analysed in 293 human cells by simple transfection. Localization analysis in 
the MMR deficient LoVo cell line was not feasible as it resulted in cellular suffering and apoptosis related to the 
re-establishment of a defective MMR (data not shown). 
The EGFP-MSH2(WT) fusion protein was correctly imported through the Nuclear Pore Complex (NPC) and 
detected almost completely in the nuclear district (Figure 3a), whereas the EGFP-MSH2(p.P622L) one, known as a 
nuclear import impairing variant (Knudsen et al.2007), coexpressed with endogenous MSH6, was mainly located 
in the cytoplasm and showed a diffuse nuclear-cytoplasmic distribution pattern (Figure3b). The EGFP-
MSH2(p.D167H) variant, whose nuclear proportion was similar to the EGFP-MSH2(WT) one, was classified as 
normal in the localization study (Figure 3d). The EGFP-MSH2(p.G162R) and EGFP-MSH2(p.R359S) variants 
were associated with an abnormal subcellular localization pattern of the corresponding fusion protein (Figure 3c 
and 3e). The first one (p.G162R) was evenly spread out among nuclear and cytoplasmic compartments whereas the 
other one (p.R359S) was mostly located in the cytoplasm, showing a defective nuclear localization as the dark 
fluorescenceless nuclear shape underlines. The results of the localization study are listed in Table1 and shown in 
Figure 3. 
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Figure 3: Localization analysis of recombinant wild type and mutated EGFP-MSH2 fusion proteins transiently expressed in 
293 MMR proficient cells. Nuclei were stained with 4’,6-diamino-2-phenylindole ( DAPI) and detected by direct fluorescence 
analysis 24h after transfection. a)Nuclear expression of EGFP-MSH2(WT) (normal localization ctrl) b)Cytoplasmic expression 
of EGFP-MSH2(P622L) (abnormal localization ctrl) c)Mainly cytoplasmic expression of EGFP-MSH2(G162R) mutation 
similar to abnormal localization ctrl d)Nuclear expression of EGFP-MSH2(D167H) variant similar to EGFP-MSH2WT 
e)Exclusively cytoplasmic location of EGFP-MSH2(R359S) mutation which hinders the nuclear import. (original magnification 
630X) 
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DISCUSSION 
HNPCC is an hereditary form of colorectal cancer associated with germline deleterious defects in 
postreplicative DNA MMR genes, mainly MLH1, MSH2 and MSH6 (de la Chapelle 2004, Peltomaki 2005). 
The effectiveness of HNPCC genetic testing deals with the identification of healthy carriers who can be 
counselled regarding the risk of colorectal cancer and enrolled in surveillance programmes. For a clinically useful 
genetic counselling it is necessary to ascertain the nature of the inherited MMR genes germline mutation and the 
role played in cancer risk. Such characterization, unambiguous in case of mutations that result in premature 
truncated proteins, can be more difficult for nontruncating variants. 
A significant fraction (20-25%) of HNPCC related MSH2 germline mutations deals with single aminoacid 
changes often associated with atypical clinical phenotypes (Peltomaki and Vasen 2004, Ollila et al. 2006). When 
linkage analysis are not feasible and the biochemical significance of the alteration is uncertain, the nature of the 
mutation should be functionally characterized before confidently assigning a pathogenetic role. 
As functional characterization of MSH2 missense variants can be considered a developing area of interest, the 
present study attempt to contribute to this trend analyzing 3 nontruncating MSH2 mutations, found in suspected 
HNPCC families, by a rather new approach. 
The 3 missense mutations we studied shared significant genetic similarities: they affected conserved amino acid 
residues, caused non conservative amino acid changes, were not reported among the known polymorphisms listed 
in the inSiGHT database and were absent in a control panel of 100 healthy individuals. Although these features are 
typical of deleterious mutations, their HNPCC causative role was to be ascertained by functional tools. Germline 
alterations were analyzed in a homologous human MMR system by investigating distinct functional properties 
mainly associated with stability and localization of the mutated proteins. To date and according to our knowledge, 
MSH2 missense mutations functional analysis dealing with the alteration of the subcellular localization are not 
available in the literature. 
First of all, we evaluated the MSH2 and MSH6 steady-state protein levels to determine the effects of MSH2 
missense mutations on protein stability. As previously showed by other Authors (Raevaara et al. 2005), to 
effectively detect decreases in protein quantity and obtain reliable data about protein stability, a sensitive 
expression system is required. Thus, recombinant protein variants were transiently co-expressed in human MSH2-
deficient LoVo cells. Two (p.G162R and p.R359S) out of the three variants were expressed in significantly lower 
amounts than the wild type protein, suggesting that these aminoacid replacements indirectly affect MMR 
efficiency through the alteration of the mutant protein stability. Both the variants resulting in decreased protein 
levels deal with substitutions of amino acids involved in protein folding. In particular, Glycine distorts α-helical 
structures whereas Arginine, given the larger dimension, shows a propensity to be surface exposed (Pacios 2001, 
Duclohier 2004). Thus, as misfolded variants are often targeted for degradation (Goldberg 2003), it is not 
surprising that a single amino acid change, which interfere with normal protein structure, could affect the stability 
of the gene product and result in a reduced expression of the protein. 
This finding was supported by the IHC analysis, which showed, for both mutations, the loss of MSH2 protein in 
tumour tissues. The fact that variants associated with reduced in vitro expression of the corresponding protein 
show a complete loss of MSH2 in IHC analyses can simply be related to differences in protein abundance in vivo 
and in vitro. 
All the mutations analysed retained the MSH2/MSH6 heterodimerizing ability in our GST pull-down assay. 
This is not surprising, as none of the variants was located in the MSH6-interaction region. However, even the 
complete deletion of the c-terminal interaction domain, linked to the p.Glu878fsX3 mutation used as a control, did 
not abolish the interacting ability. This finding, explained by the fact that MSH2 exhibits 2 distinct MSH6 
interaction regions (codons 378-625 and 875-934) (Guerrette et al. 1998), makes the reliability and usefulness of 
pulldown-based assays methods questionable. Such uncertainty is proved by Ollila’s co-immunoprecipitation assay 
results, according to which all the variants, included those located in the interaction regions, maintained the 
heterodimerizing ability (Ollila et al. 2006). 
To date, MSH2 missense variants functional consequences, included the heterodimer formation, were mainly 
studied by yeast based assays (Ellison et al. 2001, Gammie et al. 2007). Such assays rely on the expression of a 
particular phenotype in a heterologous system which shares a significant but not complete rate of homology with 
the human one (Shcherbakova and Kunkel 1999, Shimodaira et al. 1999, Trojan et al. 2002). As it is formally 
possible that missense mutations might be deleterious only in certain genetic contexts (Heck et al. 2006), the 
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designation as pathogenic for these mutations could be inaccurate and the yeast system could prove to be an 
inadequate model for human functions analysis. 
In order to overcome the hurdles, both in the use of heterologous yeast systems and in the reliability of pull-
down assays, we set up an alternative approach analyzing the subcellular localization of the mutated variants in a 
human expression system. In such approach, the localization assay acquires a double extent: provides hints about 
the ability of the mutated protein to correctly move into the nucleus and can be indirectly considered as an 
informative test about the MSH2/MSH6 heterodimerizing skill of the variants. Indeed, although able to form 
complexes with the nuclear import factors importin α3/β, up to date MSH2 protein is considered not to contain any 
classical Nuclear Localization Signal (NLS) sequences. It is possible that this MMR protein enters the nucleus 
hooked by its heterodimerizing partners, primarily MSH6. Indeed, MSH6 exhibits several aminoacidic clusters, 
peculiar to typical NLS, which are utilized to actively drive the preformed cytoplasmic MutSα complex into the 
nucleus (Christmann and Kaina 2000, Knudsen et al. 2007). As expected, the wild type MSH2 protein was 
detected almost completely in the nucleus, whereas p.P622L variant, already predicted to be pathogenetic (Heinen 
et al. 2002, Gammie et al. 2007, Knudsen et al. 2007), showed a reduced nuclear proportion when compared to the 
WT form. In this reliable grading system, two out of the three variants analysed (p.G162R and p.R359S) were 
associated with an altered subcellular localization, which can be suggestive of an incorrect MSH2/MSH6 
heterodimerization that affects the nuclear import of MutSα complex. 
A further pathogenicity assessment of the variants under study was achieved by complementing 
expression/localization assays results with computational data. The SIFT software predicted the functional results 
for 2 out of 3 variants (p.G162R and p.R359S), whereas for one amino acid substitution (p.D167H) the alignment-
based prediction and functional analysis gave conflicting results, accordingly to the estimated percentage of failure 
in correct prediction (Chan et al. 2007, Takahashi et al. 2007). 
The localization analysis classification of the investigated variants as either pathogenic or non-pathogenic was 
supported by clinical and genetic features indicative of HNPCC, such as family cancer history, occurrence of MSI 
and MMR gene expression abnormalities. Mutations shown to cause severe defects in our localization assay 
(p.G162R and p.R359S) were mirrored by phenotypic characteristics of typical HNPCC, including strong family 
history of colon cancer, high MSI and loss of MSH2/MSH6 expression in tumour tissues. Moreover, consistent 
with our views, Gammie’s and Ollila’s recent works, through a yeast-based functional assay and a repair efficiency 
assessment respectively, assigned to the same variants a HNPCC causative role (Ollila et al. 2006, Gammie et al. 
2007). On the contrary, the p.D167H mutation, functionally classified as a likely harmless variant, was detected in 
a young patient belonging to a mild colorectal cancer family and was associated with a negative immuno-staining 
for MLH1 protein (Scartozzi et al. 2002). Since no mutation was found in MLH1 gene, the immunohistochemical 
result could be hypothetically related to a somatic inactivation occurred during the tumorigenesis or to epigenetic 
silencing (promoter hypermethylation) frequent in sporadic colorectal cancer. Such a hypothesis would suggest a 
further analysis of the MLH1 promoter methylation status. Consistent with our views, recently published data also 
indicate this mutation as non-pathogenetic (Gammie et al. 2007). In the light of such considerations, proband’s 
cancer development was probably not to be ascribed to the MSH2 missense variant, which can be presumably 
considered a rare polymorphism. 
In conclusion, the subcellular localization assay, performed in a human homologous system, reliably classifies 
as pathogenetic two MSH2 nontruncating alterations (p.G162R and p.R359S) providing a useful tool for MSH2 
variants pathogenicity assessment. Our findings also illustrate the importance of combining genetic and clinical 
observations with data from functional assays to state with confidence whether a missense mutation is likely to be 
the causative factor for cancer development in HNPCC families. Elucidation of the missense mutations 
pathogenetic role may increase the effectiveness of genetic testing programs and facilitate the planning of 
appropriate preventive strategies of high risk mutation carriers from family segregating such mutations. 
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